Skip to content

All updates

19 NovThu
  1. Marijuana Moment (psychedelics policy only)42

    US House veterans committee holds hearing on psychedelic therapies for military veterans

    A US House Veterans' Affairs health subcommittee held a Wednesday hearing on veterans' access to psychedelic-assisted therapies, with VA officials and researchers testifying. The VA's Andrew Gradison said the department is running 21 active clinical studies on psychedelics, including an August-announced psilocybin trial in veterans with treatment-resistant depression.

17 NovTue
  1. Marijuana Moment (psychedelics policy only)40

    US House Veterans' Affairs health subcommittee to hold hearing on psychedelic-assisted therapies for veterans

    The House Veterans' Affairs Subcommittee on Health will hold a Wednesday hearing titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward," with VA officials, medical professionals and researchers testifying. A VA official's written testimony says the department is conducting 21 active clinical studies on psychedelics, including a trial announced in August on psilocybin for veterans with treatment-resistant depression.

14 NovSat
  1. The Microdose (UC Berkeley BCSP)62

    FDA said to end priority voucher program as Compass Pathways files psilocybin application

    Reuters reported that the US Food and Drug Administration is ending the Commissioner's National Priority Voucher program, which had compressed a 10-12 month drug review to 1-2 months. Three psychedelics-related voucher holders are affected, including Compass Pathways' COMP360 for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder and Transcend Therapeutics' methylone for PTSD.

13 NovFri
  1. Psychedelic Alpha48

    HHS taps Mark Cuban's company to develop ibogaine for PTSD and commits $20M for real-world evidence network

    The U.S. Department of Health and Human Services said it will tap Mark Cuban's company to develop ibogaine for post-traumatic stress disorder and commit $20 million to a real-world evidence network. HHS Secretary RFK Jr. gave the update at a press conference, where VA Senior Advisor Andrew Gradison stood in for VA Secretary Doug Collins.

10 NovTue
  1. Federal Register: DEA and FDA documents (US)40

    DEA proposes 2027 production quotas for Schedule I and II controlled substances and list I chemicals

    The US Drug Enforcement Administration has proposed 2027 aggregate production quotas for Schedule I and II controlled substances and an assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine and phenylpropanolamine. Written comments are due by December 10, 2026, under Docket No. DEA-1730P, after which the Administrator will publish a final order.

4 NovWed
2 NovMon
29 OctThu
  1. Lucid News58

    US federal health officials outline pre-approval groundwork for psychedelic medicines

    Officials from HHS, the FDA, the VA and ARPA-H described at The Psychedelic Healthcare Forum on Oct. 15 how an April executive order has reshaped federal preparation for psychedelic medicines. HHS Deputy General Counsel Matt Zorn said the order does not change statutory or regulatory standards, while the VA has designated 10 medical centres as Phase 1 lead sites and estimated around 100,000 veterans would qualify for psychedelic-assisted therapy immediately upon approval. The FDA's Dr Valentina Mantua said the agency oversees approximately 433 Investigational New Drug applications and has already requested REMS proposals from developers, and ARPA-H's Dr Al Bugazia cited cardiotoxicity and QTc prolongation risks, the lack of a domestic GMP manufacturer and a DEA manufacturing quota of just over 200 grams as obstacles for ibogaine research.

23 OctFri
  1. The Microdose (UC Berkeley BCSP)44

    ICER to review Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression

    The Institute for Clinical and Economic Review announced on Wednesday it will evaluate the clinical effectiveness and cost of Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression, with results to be discussed at the May 2027 meeting of the New England Comparative Effectiveness Public Advisory Council.

22 OctThu
9 OctFri
  1. Lucid News63

    New Mexico health department draft psilocybin rules draw rebuke at public hearing

    Medical providers, veterans, legal experts and the legislative sponsor of New Mexico's Medical Psilocybin Act criticised draft rules 7.35.3 and 7.35.2 NMAC at an Oct. 2 public hearing before the New Mexico Department of Health, arguing the proposed prescriber gateway, landlord consent requirements and staffing ratios exceed the statute and could block access. The department is accelerating the program's launch to December 2026, a year ahead of the statutory deadline. Speakers said the rules would require an in-person exam with a certifying clinician, patient identification cards and up to 30 days of state review, and that landlord sign-off for homebound patients and leased healing centres conflicts with fair housing law; some clinical educators praised the draft training and supervision standards. Sixteen advocacy and clinical organisations have asked Rep. Nathan P. Small to add $500,000 for the Treatment Equity Fund and $500,000 for University of New Mexico palliative research.

5 OctMon
  1. FDA: press announcements (US)62

    FDA seeks public input on early-phase ibogaine trial design

    The US Food and Drug Administration has issued a request for information on approaches it is considering for the design of early-phase clinical trials of ibogaine drug products, and is seeking public comment.

    Why it matters: The request sets out the protocol questions the agency wants answered, including a starting dose cap, so researchers and sponsors can see what evidence the FDA expects before early-phase ibogaine trials proceed.

30 SepWed
  1. MAPS62

    MAPS opposes DEA proposal to place five tryptamines in Schedule I

    MAPS has stated its opposition to a DEA proposal to place five little-known psychedelic compounds, 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT, in Schedule I of the Controlled Substances Act. The organisation says this is the agency's second attempt at the same scheduling action, after an earlier version was withdrawn in 2022 following pushback from researchers and legal advocates.

23 SepWed
18 SepFri
15 AugSat
8 JunMon
  1. TGA: interim scheduling decisions (Australia)62

    TGA publishes interim scheduling decisions on Poisons Standard amendments from ACMS #47 and Joint ACMS-ACCS #40

    The TGA has published its interim decisions on proposed amendments to the Poisons Standard considered at ACMS #47 and Joint ACMS-ACCS #40, and invites comment. The closing date for submissions is 10 July 2026. The notice is a summary only and does not list the substances or amendments covered.

    Why it matters: The notice marks the interim stage of scheduling, so anyone with an interest in the proposed Poisons Standard amendments has until 10 July 2026 to comment before a final decision.

28 MayThu
24 MaySun
  1. TGA: final scheduling decisions (Australia)62

    TGA publishes final Poisons Standard decisions from ACCS #40 and Joint ACMS-ACCS #39

    The TGA has published its notice of final decisions on whether to amend the Poisons Standard, following the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The publication is issued under regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990. The feed supplied only a summary, so the specific substances and outcomes are not stated here.

    Why it matters: The notice is the formal record of which scheduling proposals were accepted or rejected, so companies and prescribers can check whether a compound's legal status changed.

28 JanWed
  1. Advisory Council on the Misuse of Drugs (UK)62

    UK advisory council publishes updated review of ketamine use and harms

    The Advisory Council on the Misuse of Drugs has published an updated review of the use and harms of ketamine, following a commission from the then Minister for Policing, Fire and Crime Prevention in January 2025. The report reviews prevalence and harms of ketamine and its analogues in the UK, describes legitimate uses including treatment and research, covers emerging health harms such as hepatobiliary toxicity, and describes supply and trafficking.

    Why it matters: The review was commissioned to advise on ketamine's classification, so its findings on prevalence, hepatobiliary toxicity and supply could shape how the UK schedules the drug and its analogues.

17 Dec 2025Wed
  1. TGA: interim scheduling decisions (Australia)58

    TGA publishes interim decisions on proposed Poisons Standard amendments from ACCS #40 and Joint ACMS-ACCS #39

    The TGA has published interim decisions on proposed amendments to the Poisons Standard arising from the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The notice invites comment, with a closing date of 23 January 2026. The feed gave no further detail on which substances or schedules the interim decisions cover.